Skip to main content
SpringerLink
Log in

Molecular Pathology of Breast Cancer

  • Chapter
  • First Online:
Molecular Surgical Pathology

Abstract

Breast cancer is the most common cancer affecting women, with an estimated 250,000 new cases in 2011 in the US alone, and 1.5 million worldwide. It is one of the first major diseases where basic laboratory research has had a large impact on the routine clinical management of patients, ranging from detection, to diagnosis, to therapy. Molecular approaches to pathology, in particular, have had an enormous influence, especially in the areas of diagnosis and therapeutic decision-making. The topic of molecular pathology in breast cancer is very large and evolving far too rapidly to cover completely in a chapter of this nature. This chapter will primarily focus on reviewing aspects that are already in routine clinical use, some of the more promising applications on the near horizon, and scientific questions that are currently at the forefront of translational research. From an etiological point of view, the molecular pathology of breast cancer is the result of molecular abnormalities occurring in important normal processes, including the gross, microscopic, and molecular anatomy of the breast, breast development, and adult physiology—which is where we begin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Suggested Reading

  • Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203:661–71.

    Article  PubMed  Google Scholar 

  • Al-Kuraya K, Schraml P, Torhorst J, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 2004;64:8534–40.

    Article  CAS  PubMed  Google Scholar 

  • Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol. 2010;23 Suppl 2:S52–9.

    Article  CAS  PubMed  Google Scholar 

  • Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol. 2000;113:171–5.

    Article  CAS  PubMed  Google Scholar 

  • Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001;8:47–61.

    Article  CAS  PubMed  Google Scholar 

  • Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 2002;4:197–201.

    Article  CAS  PubMed  Google Scholar 

  • Anderson E, Clarke RB. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia. 2004;9:3–13.

    Article  PubMed  Google Scholar 

  • Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999;59:2011–7.

    CAS  PubMed  Google Scholar 

  • Arriola E, Rodriguez-Pinilla SM, Lambros MB, et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 2007;106:181–9.

    Article  CAS  PubMed  Google Scholar 

  • Badve SS, Baehner FL, Gray RP, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26:2473–81.

    Article  PubMed  Google Scholar 

  • Bane AL, Beck JC, Bleiweiss I, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol. 2007;31:121–8.

    Article  PubMed  Google Scholar 

  • Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer. 1996;74:1445–51.

    Article  CAS  PubMed  Google Scholar 

  • Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.

    Article  CAS  PubMed  Google Scholar 

  • Bean GR, Bryson AD, Pilie PG, et al. Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res. 2007;13:6834–41.

    Article  CAS  PubMed  Google Scholar 

  • Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia. 2009;14:55–66.

    Article  PubMed  Google Scholar 

  • Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66:4636–44.

    Article  CAS  PubMed  Google Scholar 

  • Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005;19:833–42.

    Article  PubMed  CAS  Google Scholar 

  • Borresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003;21:292–300.

    Article  CAS  PubMed  Google Scholar 

  • Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43:867–76.

    Article  CAS  PubMed  Google Scholar 

  • Brownstein MH, Wolf M, Bikowski JB. Cowden’s disease: a cutaneous marker of breast cancer. Cancer. 1978;41:2393–8.

    Article  CAS  PubMed  Google Scholar 

  • Buyse M, Loi S, van’t Veer LJ, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183–92.

    Article  CAS  PubMed  Google Scholar 

  • Caldas C, Aparicio SA. The molecular outlook. Nature. 2002;415:484–5.

    Article  CAS  PubMed  Google Scholar 

  • Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008;26:729–35.

    Article  PubMed  Google Scholar 

  • Ceriani RL, Contesso GP, Nataf BM. Hormone requirement for growth and differentiation of the human mammary gland in organ culture. Cancer Res. 1972;32:2190–6.

    CAS  PubMed  Google Scholar 

  • Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev. 1990;11:266–301.

    Article  CAS  PubMed  Google Scholar 

  • Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 1997;57:4987–91.

    CAS  PubMed  Google Scholar 

  • Clarke RB, Anderson E, Howell A, Potten CS. Regulation of human breast epithelial stem cells. Cell Prolif. 2003;36:45–58.

    Article  CAS  PubMed  Google Scholar 

  • Clarke C, Sandle J, Lakhani SR. Myoepithelial cells: pathology, cell separation and markers of myoepithelial differentiation. J Mammary Gland Biol Neoplasia. 2005;10:273–80.

    Article  PubMed  Google Scholar 

  • Coletta RD, Christensen K, Reichenberger KJ, et al. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci USA. 2004;101:6478–83.

    Article  CAS  PubMed  Google Scholar 

  • Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids. 2000;65:571–7.

    Article  CAS  PubMed  Google Scholar 

  • Correa Geyer F, Reis-Filho JS. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int J Surg Pathol. 2009;17:285–302.

    Article  PubMed  Google Scholar 

  • Courjal F, Cuny M, Simony-Lafontaine J, et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 1997;57:4360–7.

    CAS  PubMed  Google Scholar 

  • Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132–9.

    Article  CAS  PubMed  Google Scholar 

  • Cowen PN, Teasdale J, Jackson P, Reid BJ. Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay. Histopathology. 1990;17:319–25.

    Article  CAS  PubMed  Google Scholar 

  • Crawford YG, Gauthier ML, Joubel A, et al. Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell. 2004;5:263–73.

    Article  CAS  PubMed  Google Scholar 

  • Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721–35.

    Article  CAS  PubMed  Google Scholar 

  • Cuny M, Kramar A, Courjal F, et al. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res. 2000;60:1077–83.

    CAS  PubMed  Google Scholar 

  • Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 2008;13:620–30.

    Article  CAS  PubMed  Google Scholar 

  • Dal Lago L, Durbecq V, Desmedt C, et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther. 2006;5:2572–9.

    Article  CAS  PubMed  Google Scholar 

  • Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer. 2008;44:2806–12.

    Article  CAS  PubMed  Google Scholar 

  • Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science. 1996;274:2057–9.

    Article  CAS  PubMed  Google Scholar 

  • Deroo BJ, Hewitt SC, Collins JB, Grissom SF, Hamilton KJ, Korach KS. Profile of estrogen-responsive genes in an estrogen-specific mammary gland outgrowth model. Mol Reprod Dev. 2009;76:733–50.

    Article  CAS  PubMed  Google Scholar 

  • Dewar R, Fadare O, Gilmore H, Gown AM. Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology. Arch Pathol Lab Med. 2011;135:422–9.

    PubMed  Google Scholar 

  • Dhesy-Thind B, Pritchard KI, Messersmith H, O’Malley F, Elavathil L, Trudeau M. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat. 2008;109:209–29.

    Article  CAS  PubMed  Google Scholar 

  • Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464:999–1005.

    Article  CAS  PubMed  Google Scholar 

  • Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994–4008.

    Article  CAS  PubMed  Google Scholar 

  • Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005;29:1221–7.

    Article  PubMed  Google Scholar 

  • Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008;26:1059–65.

    Article  CAS  PubMed  Google Scholar 

  • Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat. 2005;93:3–11.

    Article  CAS  PubMed  Google Scholar 

  • Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56:265–71.

    CAS  PubMed  Google Scholar 

  • Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 1996;56:471–4.

    CAS  PubMed  Google Scholar 

  • Elbauomy Elsheikh S, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007;9:R23.

    Article  PubMed  CAS  Google Scholar 

  • Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PR), by ligand-binding assay compared with ER, PR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000;89:111–7.

    Article  CAS  PubMed  Google Scholar 

  • Engel RH, Kaklamani VG. HER2-positive breast cancer: current and future treatment strategies. Drugs. 2007;67:1329–41.

    Article  CAS  PubMed  Google Scholar 

  • Esteban JM, Ahn C, Battifora H, Felder B. Quantitative immunohistochemical assay for hormonal receptors: technical aspects and biological significance. J Cell Biochem Suppl. 1994;19:138–45.

    CAS  PubMed  Google Scholar 

  • Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355:560–9.

    Article  CAS  PubMed  Google Scholar 

  • Fan C, Prat A, Parker JS, et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics. 2011;4:3.

    Article  PubMed  Google Scholar 

  • Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 1995;9:2364–72.

    Article  CAS  PubMed  Google Scholar 

  • Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660–71.

    Article  CAS  PubMed  Google Scholar 

  • Faverly D, Holland R, Burgers L. An original stereomicroscopic analysis of the mammary glandular tree. Virchows Arch A Pathol Anat Histopathol. 1992;421:115–9.

    Article  CAS  PubMed  Google Scholar 

  • Fendrick JL, Raafat AM, Haslam SZ. Mammary gland growth and development from the postnatal period to postmenopause: ovarian steroid receptor ontogeny and regulation in the mouse. J Mammary Gland Biol Neoplasia. 1998;3:7–22.

    Article  CAS  PubMed  Google Scholar 

  • Fisher B, Redmond C, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6.

    Article  CAS  PubMed  Google Scholar 

  • Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol. 1983;1:227–41.

    CAS  PubMed  Google Scholar 

  • Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966–78.

    CAS  PubMed  Google Scholar 

  • Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer. 1995;72:805–12.

    Article  CAS  PubMed  Google Scholar 

  • Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482–5.

    Article  CAS  PubMed  Google Scholar 

  • Francis GD, Dimech M, Giles L, Hopkins A. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol. 2007;60:1277–83.

    Article  PubMed  Google Scholar 

  • Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–90.

    Article  CAS  PubMed  Google Scholar 

  • Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49:22–34.

    Article  CAS  PubMed  Google Scholar 

  • Gaffney DK, Brohet RM, Lewis CM, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol. 1998;47:129–36.

    Article  CAS  PubMed  Google Scholar 

  • Geisler S, Borresen-Dale AL, Johnsen H, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res. 2003;9:5582–8.

    CAS  PubMed  Google Scholar 

  • Gelber RD, Gelber S. Facilitating consensus by examining patterns of treatment effects. Breast. 2009;18 Suppl 3:S2–8.

    Article  PubMed  Google Scholar 

  • Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23:7265–77.

    Article  CAS  PubMed  Google Scholar 

  • Goepfert TM, McCarthy M, Kittrell FS, et al. Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells. FASEB J. 2000;14:2221–9.

    Article  CAS  PubMed  Google Scholar 

  • Goodwin PJ, Phillips KA, West DW, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol. 2012;30:19–26.

    Article  PubMed  Google Scholar 

  • Greene GL, Press MF. Structure and dynamics of the estrogen receptor. J Steroid Biochem. 1986;24:1–7.

    Article  CAS  PubMed  Google Scholar 

  • Gudjonsson T, Adriance MC, Sternlicht MD, Petersen OW, Bissell MJ. Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia. 2005;10:261–72.

    Article  PubMed  Google Scholar 

  • Gusterson B. Do ‘basal-like’ breast cancers really exist? Nat Rev Cancer. 2009;9:128–34.

    Article  CAS  PubMed  Google Scholar 

  • Gusterson BA, Ross DT, Heath VJ, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005;7:143–8.

    Article  CAS  PubMed  Google Scholar 

  • Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684–9.

    Article  CAS  PubMed  Google Scholar 

  • Hamann U, Sinn HP. Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res Treat. 2000;59:185–92.

    Article  CAS  PubMed  Google Scholar 

  • Hammond ME, Fitzgibbons PL, Compton CC, et al. College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. Arch Pathol Lab Med. 2000;124:958–65.

    CAS  PubMed  Google Scholar 

  • Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010a;134:907–22.

    PubMed  Google Scholar 

  • Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010b;134:e48–72.

    CAS  PubMed  Google Scholar 

  • Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000;19:6102–14.

    Article  CAS  PubMed  Google Scholar 

  • Hart LL, Davie JR. The estrogen receptor: more than the average transcription factor. Biochem Cell Biol. 2002;80:335–41.

    Article  CAS  PubMed  Google Scholar 

  • Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.

    CAS  PubMed  Google Scholar 

  • Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res. 2008;14:4038–44.

    Article  CAS  PubMed  Google Scholar 

  • Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69:4116–24.

    Article  CAS  PubMed  Google Scholar 

  • Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8:R76.

    Article  PubMed  CAS  Google Scholar 

  • Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev. 2004;25:869–98.

    Article  CAS  PubMed  Google Scholar 

  • Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol. 2005;67:285–308.

    Article  CAS  PubMed  Google Scholar 

  • Hill CB, Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol. 2005;123:36–44.

    Article  PubMed  Google Scholar 

  • Holst CR, Nuovo GJ, Esteller M, et al. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 2003;63:1596–601.

    CAS  PubMed  Google Scholar 

  • Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007;39:655–60.

    Article  CAS  PubMed  Google Scholar 

  • Honrado E, Osorio A, Palacios J, Benitez J. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene. 2006;25:5837–45.

    Article  CAS  PubMed  Google Scholar 

  • Honrado E, Osorio A, Milne RL, et al. Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pathol. 2007;20:1298–306.

    Article  CAS  PubMed  Google Scholar 

  • Hovey RC, Trott JF, Vonderhaar BK. Establishing a framework for the functional mammary gland: from endocrinology to morphology. J Mammary Gland Biol Neoplasia. 2002;7:17–38.

    Article  PubMed  Google Scholar 

  • Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–2.

    Article  CAS  PubMed  Google Scholar 

  • Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.

    Article  PubMed  CAS  Google Scholar 

  • Hu M, Yao J, Carroll DK, et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008;13:394–406.

    Article  CAS  PubMed  Google Scholar 

  • Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 1998;58:4023–37.

    CAS  PubMed  Google Scholar 

  • Hutson SW, Cowen PN, Bird CC. Morphometric studies of age related changes in normal human breast and their significance for evolution of mammary cancer. J Clin Pathol. 1985;38:281–7.

    Article  CAS  PubMed  Google Scholar 

  • Huvos AG, Lucas Jr JC, Foote Jr FW. Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med. 1973;73:1078–82.

    CAS  PubMed  Google Scholar 

  • Jansson T, Inganas M, Sjogren S, et al. p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol. 1995;13:2745–51.

    CAS  PubMed  Google Scholar 

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  • Jerevall PL, Ma XJ, Li H, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer. 2011;104:1762–9.

    Article  CAS  PubMed  Google Scholar 

  • Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer. 1997;33:362–71.

    Article  CAS  PubMed  Google Scholar 

  • Jordan C. Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther. 2002;24(Suppl A):A3–16.

    Article  CAS  PubMed  Google Scholar 

  • Jordan VC, Wolf MF, Mirecki DM, Whitford DA, Welshons WV. Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. Crit Rev Clin Lab Sci. 1988;26:97–152.

    Article  CAS  PubMed  Google Scholar 

  • Kallioniemi A, Kallioniemi OP, Piper J, et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA. 1994;91:2156–60.

    Article  CAS  PubMed  Google Scholar 

  • Kampa M, Pelekanou V, Castanas E. Membrane-initiated steroid action in breast and prostate cancer. Steroids. 2008;73:953–60.

    Article  CAS  PubMed  Google Scholar 

  • Karni R, Jove R, Levitzki A. Inhibition of pp 60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene. 1999;18:4654–62.

    Article  CAS  PubMed  Google Scholar 

  • Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297:2360–72.

    Article  CAS  PubMed  Google Scholar 

  • Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer. 2006;13:39–49.

    Article  CAS  PubMed  Google Scholar 

  • Keaveney M, Klug J, Dawson MT, et al. Evidence for a previously unidentified upstream exon in the human oestrogen receptor gene. J Mol Endocrinol. 1991;6:111–5.

    Article  CAS  PubMed  Google Scholar 

  • Keith WN, Douglas F, Wishart GC, et al. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer. 1993;29A:1469–75.

    Article  CAS  PubMed  Google Scholar 

  • Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155:337–42.

    Article  CAS  PubMed  Google Scholar 

  • Klingbeil P, Natrajan R, Everitt G, et al. CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res Treat. 2010;120:95–109.

    Article  CAS  PubMed  Google Scholar 

  • Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142–53.

    Article  CAS  PubMed  Google Scholar 

  • Kuter I, Gee JM, Hegg R, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat. 2012;133(1):237–46.

    Article  CAS  PubMed  Google Scholar 

  • LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305:1305–14.

    Article  CAS  PubMed  Google Scholar 

  • Lacroix-Triki M, Geyer FC, Lambros MB, et al. Beta-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. Mod Pathol. 2010;23:1438–48.

    Article  CAS  PubMed  Google Scholar 

  • Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138–45.

    Article  CAS  PubMed  Google Scholar 

  • Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310–8.

    Article  CAS  PubMed  Google Scholar 

  • Larson PS, de las Morenas A, Bennett SR, Cupples LA, Rosenberg CL. Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol. 2002;161:283–90.

    Article  PubMed  Google Scholar 

  • Larson PS, Schlechter BL, de las Morenas A, Garber JE, Cupples LA, Rosenberg CL. Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues. J Clin Oncol. 2005;23:8613–9.

    Article  CAS  PubMed  Google Scholar 

  • Lee S, Medina D, Tsimelzon A, et al. Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol. 2007;171:252–62.

    Article  CAS  PubMed  Google Scholar 

  • Lee S, Stewart S, Nagtegaal I, et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res 2012;72(17):4574–86.

    Google Scholar 

  • Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res. Treat. 2008;108:351–61.

    Article  CAS  PubMed  Google Scholar 

  • Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64–7.

    Article  CAS  PubMed  Google Scholar 

  • Liedtke C, Hatzis C, Symmans WF, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Pathol. 2009;27:3185–91.

    Google Scholar 

  • Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA. 2008;105:1680–5.

    Article  CAS  PubMed  Google Scholar 

  • Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–71.

    Article  CAS  PubMed  Google Scholar 

  • Lockwood CA, Ricciardelli C, Raymond WA, Seshadri R, McCaul K, Horsfall DJ. A simple index using video image analysis to predict disease outcome in primary breast cancer. Int J Cancer. 1999;84:203–8.

    Article  CAS  PubMed  Google Scholar 

  • Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25:1239–46.

    Article  CAS  PubMed  Google Scholar 

  • Lubinski J, Gorski B, Huzarski T, et al. BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat. 2006;99:71–6.

    Article  CAS  PubMed  Google Scholar 

  • Lukas J, Niu N, Press MF. p53 Mutations and expression in breast carcinoma in situ. Am J Pathol. 2000;156:183–91.

    Article  CAS  PubMed  Google Scholar 

  • Lydon JP, Ge G, Kittrell FS, Medina D, O’Malley BW. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res. 1999;59:4276–84.

    CAS  PubMed  Google Scholar 

  • Lynch HT, Mulcahy GM, Harris RE, Guirgis HA, Lynch JF. Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma. Cancer. 1978;41:2055–64.

    Article  CAS  PubMed  Google Scholar 

  • Lynch HT, Watson P, Conway TA, et al. DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. Arch Intern Med. 1993;153:1979–87.

    Article  CAS  PubMed  Google Scholar 

  • Lynch HT, Lynch J, Conway T, et al. Hereditary breast cancer and family cancer syndromes. World J Surg. 1994;18:21–31.

    Article  CAS  PubMed  Google Scholar 

  • Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol. 1998;29:1140–4.

    Article  CAS  PubMed  Google Scholar 

  • Lynch HT, McComb RD, Osborn NK, et al. Predominance of brain tumors in an extended Li-Fraumeni (SBLA) kindred, including a case of Sturge-Weber syndrome. Cancer. 2000;88:433–9.

    Article  CAS  PubMed  Google Scholar 

  • Lynch HT, Kaurah P, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and ­prophylactic total gastrectomy. Cancer. 2008;112:2655–63.

    Article  PubMed  Google Scholar 

  • Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5:607–16.

    Article  CAS  PubMed  Google Scholar 

  • Ma XJ, Salunga R, Dahiya S, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 2008;14:2601–8.

    Article  CAS  PubMed  Google Scholar 

  • Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park). 2009;23:133–42.

    Google Scholar 

  • Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–8.

    Article  CAS  PubMed  Google Scholar 

  • Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 2006;66:8297–308.

    Article  CAS  PubMed  Google Scholar 

  • Marchio C, Iravani M, Natrajan R, et al. Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol. 2009;218:301–15.

    Article  CAS  PubMed  Google Scholar 

  • Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996;77:697–709.

    Article  CAS  PubMed  Google Scholar 

  • Marcus JN, Watson P, Page DL, et al. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat. 1997;44:275–7.

    Article  CAS  PubMed  Google Scholar 

  • Mariani G, Fasolo A, De Benedictis E, Gianni L. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol. 2009;6:93–104.

    Article  CAS  PubMed  Google Scholar 

  • Marotti JD, Collins LC, Hu R, Tamimi RM. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol. 2010;23:197–204.

    Article  CAS  PubMed  Google Scholar 

  • Marsh DJ, Dahia PL, Caron S, et al. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet. 1998;35:881–5.

    Article  CAS  PubMed  Google Scholar 

  • Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 2006;98:1285–91.

    Article  CAS  PubMed  Google Scholar 

  • McBryan J, Howlin J, Kenny PA, Shioda T, Martin F. ERalpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis. Oncogene. 2007;26:6406–19.

    Article  CAS  PubMed  Google Scholar 

  • McCarthy A, Savage K, Gabriel A, Naceur C, Reis-Filho JS, Ashworth A. A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol. 2007;211:389–98.

    Article  CAS  PubMed  Google Scholar 

  • Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol. 2000;182:150–62.

    Article  CAS  PubMed  Google Scholar 

  • Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol. 2001;19:329–35.

    CAS  PubMed  Google Scholar 

  • Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.

    Article  CAS  PubMed  Google Scholar 

  • Mitani Y, Li J, Weber RS, et al. Expression and regulation of the DeltaN and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings. Am J Pathol. 2011;179:391–9.

    Article  CAS  PubMed  Google Scholar 

  • Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol. 2010;23:1029–39.

    Article  CAS  PubMed  Google Scholar 

  • Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545–54.

    Article  CAS  PubMed  Google Scholar 

  • Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA. 1992;89:7262–6.

    Article  CAS  PubMed  Google Scholar 

  • Mueller SO, Clark JA, Myers PH, Korach KS. Mammary gland development in adult mice requires epithelial and stromal estrogen receptor alpha. Endocrinology. 2002;143:2357–65.

    Article  CAS  PubMed  Google Scholar 

  • Muggerud AA, Ronneberg JA, Warnberg F, et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res. 2010;12:R3.

    Article  PubMed  CAS  Google Scholar 

  • Naccarato AG, Viacava P, Vignati S, et al. Bio-morphological events in the development of the human female mammary gland from fetal age to puberty. Virchows Arch. 2000;436:431–8.

    Article  CAS  PubMed  Google Scholar 

  • Narod SA, Feunteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet. 1991;338:82–3.

    Article  CAS  PubMed  Google Scholar 

  • Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case–control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356:1876–81.

    Article  CAS  PubMed  Google Scholar 

  • Nass SJ, Dickson RB. Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat. 1997;44:1–22.

    Article  CAS  PubMed  Google Scholar 

  • Nassar H. Carcinomas with micropapillary morphology: clinical significance and current concepts. Adv Anat Pathol. 2004;11:297–303.

    Article  PubMed  Google Scholar 

  • Nathan B, Anbazhagan R, Clarkson P, Bartkova J, Gusterson B. Expression of BCL-2 in the developing human fetal and infant breast. Histopathology. 1994;24:73–6.

    Article  CAS  PubMed  Google Scholar 

  • Nelen MR, van Staveren WC, Peeters EA, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet. 1997;6:1383–7.

    Article  CAS  PubMed  Google Scholar 

  • Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.

    Article  CAS  PubMed  Google Scholar 

  • Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16:5222–32.

    Article  CAS  PubMed  Google Scholar 

  • Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer. 2004;11:267–75.

    Article  PubMed  Google Scholar 

  • Olivier M, Hainaut P. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin Cancer Biol. 2001;11:353–60.

    Article  CAS  PubMed  Google Scholar 

  • Osborne RJ, Merlo GR, Mitsudomi T, et al. Mutations in the p53 gene in primary human breast cancers. Cancer Res. 1991;51:6194–8.

    CAS  PubMed  Google Scholar 

  • Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5:63–9.

    Article  CAS  PubMed  Google Scholar 

  • Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

    Article  CAS  PubMed  Google Scholar 

  • Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.

    Article  CAS  PubMed  Google Scholar 

  • Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res. 2003;9:3606–14.

    CAS  PubMed  Google Scholar 

  • Panoff JE, Hurley J, Takita C, et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. Breast Cancer Res Treat. 2011;128:899–906.

    Article  CAS  PubMed  Google Scholar 

  • Park K, Kwak K, Kim J, Lim S, Han S. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol. 2005;36:634–9.

    Article  CAS  PubMed  Google Scholar 

  • Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.

    Article  PubMed  Google Scholar 

  • Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008;26:1–10.

    Article  CAS  PubMed  Google Scholar 

  • Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148–54.

    PubMed  Google Scholar 

  • Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in ­specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032–8.

    Article  PubMed  Google Scholar 

  • Perez EA, Jenkins RB, Dueck AC, et al. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol. 2011;29:651–9.

    Article  CAS  PubMed  Google Scholar 

  • Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

    Article  CAS  PubMed  Google Scholar 

  • Persons DL, Tubbs RR, Cooley LD, et al. HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch Pathol Lab Med. 2006;130:325–31.

    PubMed  Google Scholar 

  • Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA. 2009;106:18740–4.

    Article  CAS  PubMed  Google Scholar 

  • Petersen OW, Polyak K. Stem cells in the human breast. Cold Spring Harb Perspect Biol. 2010;2:a003160.

    Article  PubMed  CAS  Google Scholar 

  • Petersen OW, Hoyer PE, van Deurs B. Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res. 1987;47:5748–51.

    CAS  PubMed  Google Scholar 

  • Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348–53.

    Article  CAS  PubMed  Google Scholar 

  • Piva R, Bianchi N, Aguiari GL, Gambari R, del Senno L. Sequencing of an RNA transcript of the human estrogen receptor gene: evidence for a new transcriptional event. J Steroid Biochem Mol Biol. 1993;46:531–8.

    Article  CAS  PubMed  Google Scholar 

  • Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia. 2005;10:231–47.

    Article  PubMed  Google Scholar 

  • Porter DE, Cohen BB, Wallace MR, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg. 1994;81:1512–5.

    Article  CAS  PubMed  Google Scholar 

  • Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5:5–23.

    Article  CAS  PubMed  Google Scholar 

  • Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11:6598–607.

    Article  CAS  PubMed  Google Scholar 

  • Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354:2103–11.

    Article  CAS  PubMed  Google Scholar 

  • Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist. 2006;11:868–77.

    Article  CAS  PubMed  Google Scholar 

  • Rakha E, Ellis I, Reis-Filho J. Are triple-negative and basal-like breast cancer synonymous? Clin Cancer Res. 2008;14:618; author reply 618–9.

    Google Scholar 

  • Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer. 2006;7:153–7.

    Article  PubMed  Google Scholar 

  • Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571–81.

    Article  CAS  PubMed  Google Scholar 

  • Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52:108–18.

    Article  CAS  PubMed  Google Scholar 

  • Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49:10–21.

    Article  CAS  PubMed  Google Scholar 

  • Reis-Filho JS, Drury S, Lambros MB, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet. 2008;40:809–10; author reply 810–2.

    Google Scholar 

  • Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol. 2000a;53:688–96.

    Article  CAS  PubMed  Google Scholar 

  • Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000b;53:125–30.

    Article  CAS  PubMed  Google Scholar 

  • Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem. 2002;277:5209–18.

    Article  CAS  PubMed  Google Scholar 

  • Robinson GW. Identification of signaling pathways in early mammary gland development by mouse genetics. Breast Cancer Res. 2004;6:105–8.

    Article  CAS  PubMed  Google Scholar 

  • Robinson GW. Cooperation of signalling pathways in embryonic mammary gland development. Nat Rev Genet. 2007;8:963–72.

    Article  CAS  PubMed  Google Scholar 

  • Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.

    Article  CAS  PubMed  Google Scholar 

  • Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–85.

    Article  CAS  PubMed  Google Scholar 

  • Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312:513–6.

    Article  CAS  PubMed  Google Scholar 

  • Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004;10:331S–6.

    Article  CAS  PubMed  Google Scholar 

  • Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol. 2010;23 Suppl 2:S60–4.

    Article  PubMed  Google Scholar 

  • Serova O, Montagna M, Torchard D, et al. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet. 1996;58:42–51.

    CAS  PubMed  Google Scholar 

  • Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA. 1995;273:535–41.

    Article  CAS  PubMed  Google Scholar 

  • Shiang CY, Qi Y, Wang B, et al. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat. 2010;123:747–55.

    Article  CAS  PubMed  Google Scholar 

  • Silva CM, Shupnik MA. Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance. Mol Endocrinol. 2007;21:1499–512.

    Article  CAS  PubMed  Google Scholar 

  • Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145–53.

    Article  CAS  PubMed  Google Scholar 

  • Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268–74.

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.

    Article  CAS  PubMed  Google Scholar 

  • Smith CL, O’Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004;25:45–71.

    Article  CAS  PubMed  Google Scholar 

  • Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.

    Article  CAS  PubMed  Google Scholar 

  • Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–23.

    Article  CAS  PubMed  Google Scholar 

  • Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, Jirstrom K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 2006;12:4614–8.

    Article  CAS  PubMed  Google Scholar 

  • Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2010;119:551–8.

    Article  PubMed  Google Scholar 

  • Surmacz E, Bartucci M. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J Exp Clin Cancer Res. 2004;23:385–94.

    CAS  PubMed  Google Scholar 

  • Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol. 2009;18:125–32.

    Article  CAS  PubMed  Google Scholar 

  • Tanner MM, Tirkkonen M, Kallioniemi A, et al. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res. 1996;56:3441–5.

    CAS  PubMed  Google Scholar 

  • Tanner M, Isola J, Wiklund T, et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol. 2006;24:2428–36.

    Article  CAS  PubMed  Google Scholar 

  • Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–57.

    Article  PubMed  Google Scholar 

  • Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367–76.

    Article  CAS  PubMed  Google Scholar 

  • Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19:2714–21.

    CAS  PubMed  Google Scholar 

  • Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25:5846–53.

    Article  CAS  PubMed  Google Scholar 

  • Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26:2126–32.

    Article  CAS  PubMed  Google Scholar 

  • Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70:2085–94.

    Article  CAS  PubMed  Google Scholar 

  • van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.

    Article  PubMed  Google Scholar 

  • Van Tine BA, Crowder RJ, Ellis MJ. ER and PI3K independently modulate endocrine resistance in ER positive breast cancer. Cancer Discov. 2011;1:287–8.

    Article  PubMed  CAS  Google Scholar 

  • Vici P, Viola G, Botti C, et al. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Clin Ter. 2008;159:449–52.

    CAS  PubMed  Google Scholar 

  • Walton BJ, Morain WD, Baughman RD, Jordan A, Crichlow RW. Cowden’s disease: a further indication for prophylactic mastectomy. Surgery. 1986;99:82–6.

    CAS  PubMed  Google Scholar 

  • Wang Y, Thakur A, Sun Y, et al. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice. Cancer Res. 2007;67:3698–707.

    Article  CAS  PubMed  Google Scholar 

  • Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478–88.

    Article  PubMed  Google Scholar 

  • Watson P, Marcus JN, Lynch HT. Prognosis of BRCA1 hereditary breast cancer. Lancet. 1998;351:304–5.

    Article  CAS  PubMed  Google Scholar 

  • Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005;65:9155–8.

    Article  CAS  PubMed  Google Scholar 

  • Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141–50.

    Article  CAS  PubMed  Google Scholar 

  • Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2009;117:273–80.

    Article  CAS  PubMed  Google Scholar 

  • Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a ­retrospective of the last decade. J Pathol. 2010a;220:263–80.

    Article  CAS  PubMed  Google Scholar 

  • Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol. 2010b;4:192–208.

    Article  CAS  PubMed  Google Scholar 

  • Westbury CB, Reis-Filho JS, Dexter T, et al. Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ERalpha) in response to therapeutic radiation. J Pathol. 2009;219:131–40.

    Article  CAS  PubMed  Google Scholar 

  • Williard W, Borgen P, Bol R, Tiwari R, Osborne M. Cowden’s disease. A case report with analyses at the molecular level. Cancer. 1992;69:2969–74.

    Article  CAS  PubMed  Google Scholar 

  • Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619–29.

    Article  CAS  PubMed  Google Scholar 

  • Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10:R65.

    Article  PubMed  CAS  Google Scholar 

  • Wolaniuk A. Hormonal regulation of the development and function of the breasts and mammae. Postepy Hig Med Dosw. 1982;36:375–84.

    CAS  PubMed  Google Scholar 

  • Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.

    Article  CAS  PubMed  Google Scholar 

  • Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088–90.

    Article  CAS  PubMed  Google Scholar 

  • Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA

    Alejandro Ariel Gru M.D. & Donald Craig Allred M.D.

Authors
  1. Alejandro Ariel Gru M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald Craig Allred M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. , Molecular Pathology Laboratory, Indiana University School of Medicine, 350 West 11th Street, Rm 4010, Indianapolis, 46202, Indiana, USA

    Liang Cheng

  2. Department of Pathology, and Laboratory Medicine, Indiana University School of Medicine, 635 Barnhill Drive, Room 128, Indianapolis, 46202, Indiana, USA

    John N. Eble

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gru, A.A., Allred, D.C. (2013). Molecular Pathology of Breast Cancer. In: Cheng, L., Eble, J. (eds) Molecular Surgical Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4900-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-4900-3_6

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-4899-0

  • Online ISBN: 978-1-4614-4900-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation